Carrum Health vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 35)
Carrum Health logo

Carrum Health

NicheHealthcare

Value-Based Surgical Care Platform

Carrum Health connects self-insured employers with Centers of Excellence (COE) hospital systems through bundled payment surgical care arrangements; raised $45M Series B in 2022;

AI VisibilityBeta
Overall Score
D35
Category Rank
#553 of 596
AI Consensus
77%
Trend
stable
Per Platform
ChatGPT
40
Perplexity
40
Gemini
33

About

Carrum Health is a San Francisco-based healthcare technology company founded in 2014 by Sach Jain. It operates a value-based care platform that connects self-insured employers directly with a curated national network of Centers of Excellence (COE) — high-quality regional hospital systems and surgical facilities — through bundled payment arrangements for elective and complex surgical procedures. Rather than routing employees through standard in-network insurance plans where surgical quality varies widely, Carrum's model steers patients to top-performing surgical centers, covers travel costs when necessary, and eliminates employee out-of-pocket costs entirely for covered procedures.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

35
Overall Score
93
#553
Category Rank
#1
77
AI Consensus
80
stable
Trend
stable
40
ChatGPT
94
40
Perplexity
89
33
Gemini
94
35
Claude
92
32
Grok
98

Key Details

Category
Value-Based Surgical Care Platform
Enterprise
Tier
Niche
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.